_256_384.jpg)
News | December 08, 2021
IPM registers 6 % yoy revenue growth in Nov 2021.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
Sputnik M is a new member of the Sputnik vaccines family
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The fund aims at investing in companies that extends human healthspan
The product will be commercialized from Unichem's Ghaziabad plant
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
